Please select the option that best describes you:
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anaplastic astrocytomas with an IDH-1 mutation in a tumor board (if the health insurance company approves). How promising is the therapy? How should the difference between Ivosidenib be evaluated (as an individual compassionate use treatment)?
Answer from: Radiation Oncologist at Academic Institution
INDIGO has stirred up the blues, as can clearly be seen by the responses here. The issues raised are extremely valid and rather than rehash the critical points already brought out by both Drs. @Stea and @Lazarev, let me direct the readers to a very detailed summary paper that contextualizes these is...
Comments
Radiation Oncologist at Brown University
Excellent reference @Minesh!
Excellent reference @Minesh!
Answer from: Radiation Oncologist at Academic Institution
For patients with grade 3 IDH-mutant glioma, adjuvant therapy (after maximal safe resection) with RT followed by TMZ or PCV is generally considered the standard-of-care for all patients. Institutional practice varies regarding the choice of TMZ or PCV due to an often greater toxicity profile with PC...
As an example of a very troubling trend, I am curr...